文献速递新药、器械与细胞基因治疗研发临床试验与 GCP

药物预防老年人术后谵妄有效性的系统综述与网状Meta分析

Effectiveness of drug interventions to prevent delirium after surgery for older adults: systematic review and network meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2026-02-12

右美托咪定、糖皮质激素、褪黑素受体激动剂、帕瑞昔布、奥氮平和鼻内胰岛素在高偏倚风险试验排除后仍显示有效,其中仅糖皮质激素降低谵妄严重程度。

要点

  • 右美托咪定可有效预防老年人术后谵妄,证据在排除高偏倚风险试验后仍成立。
  • 糖皮质激素、褪黑素受体激动剂、帕瑞昔布、鼻内胰岛素和奥氮平可能有益,但证据质量中至极低。
  • 仅糖皮质激素降低谵妄严重程度,多数干预对住院时长、死亡率、认知或生活质量无影响。

核心结论

  • 右美托咪定对预防老年人术后谵妄有效,该结论在排除高偏倚风险研究后仍成立。
  • 糖皮质激素、褪黑素受体激动剂、帕瑞昔布、鼻内胰岛素和奥氮平可能有益,但证据质量为中至极低。

研究设计与样本

  • 系统综述与网状Meta分析,检索Embase、Medline和Cochrane Library截至2024年3月4日。

主要发现

  • 术后谵妄总体风险为14.5%(n=5957)。
  • 在非高偏倚风险试验中,右美托咪定OR 0.46(95%可信区间0.36至0.57),糖皮质激素OR 0.53(0.31至0.87),褪黑素受体激动剂OR 0.54(0.34至0.85)。
  • 帕瑞昔布OR 0.34(0.16至0.74),奥氮平OR 0.27(0.07至0.94),鼻内胰岛素OR 0.13(0.04至0.34)。
  • 仅糖皮质激素降低谵妄严重程度,平均差-2.42(95%可信区间-4.72至-0.12)Memorial Delirium Assessment Scale分。
  • 右美托咪定增加低血压和心动过缓但减少术后恶心呕吐,糖皮质激素不增加术后感染率。

关键数值与推荐

  • 纳入标准:随机对照试验,参与者至少60岁,使用验证的谵妄评估工具,干预为一种或多种药物预防术后谵妄。
  • 排除标准:仅局部麻醉手术、术前机械通气、治疗谵妄的干预研究。

临床怎么用

  • 右美托咪定可作为预防老年人术后谵妄的有效药物选择,但需注意低血压和心动过缓风险。
  • 糖皮质激素、褪黑素受体激动剂、帕瑞昔布、鼻内胰岛素和奥氮平可考虑潜在获益,但应知晓证据质量较低。

局限性

  • 试验注册实践不充分和核心结局集采用不完整使证据合成复杂化。
  • 部分药物干预的证据质量为中至极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify which drugs are effective at preventing delirium after surgery in adults over 60 years of age and estimate the effects on morbidity and mortality. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Embase, Medline, and Cochrane Library up to 4 March 2024. ELIGIBILITY CRITERIA: Randomised controlled trials with administration of one or more drugs for the prevention of delirium after surgery requiring general or regional anaesthesia that recruited participants at least 60 years old and used a validated delirium assessment tool to measure the outcome. Surgery under local anaesthesia only, preoperative mechanical ventilation, and studies of interventions to treat delirium were excluded. DATA EXTRACTION AND SYNTHESIS: Assessors masked to each other's decisions screened studies, extracted data, and assessed risk of bias and quality of evidence in duplicate by using the Cochrane risk of bias tool version 2 and the CINeMA tool. Bayesian arm based network meta-analysis was used to compare interventions. RESULTS: 158 trials were identified with 41 084 participants comparing 52 drug interventions. Seventeen trials were rated as being at high risk of bias. The overall risk of delirium after surgery was 14.5% (n=5957). Dexmedetomidine (odds ratio 0.46, 95% credible interval 0.36 to 0.57), corticosteroids (0.53, 0.31 to 0.87), melatonin receptor agonists (0.54, 0.34 to 0.85), parecoxib (0.34, 0.16 to 0.74), olanzapine (0.27, 0.07 to 0.94), and intranasal insulin (0.13, 0.04 to 0.34) were the most effective interventions at preventing delirium in trials not at high risk of bias. Only corticosteroids reduced the severity of delirium (mean difference -2.42 (95% credible interval -4.72 to -0.12) Memorial Delirium Assessment Scale points). Most interventions had no effect on length of stay, mortality, cognition, or quality of life. Hypotension and bradycardia were more common with dexmedetomidine, but postoperative nausea and vomiting were reduced. Postoperative infection rates were not increased by corticosteroids. CONCLUSIONS: Dexmedetomidine is effective in the prevention of postoperative delirium. This finding remains after exclusion of studies at high risk of bias. Corticosteroids, melatonin receptor agonists, parecoxib, intranasal insulin, and olanzapine have potential benefit, although evidence is of moderate to very low quality. Evidence synthesis in this area is complicated by inadequate trial registration practices and incomplete adoption of core outcome sets. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023488337.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Luney M, Holdsworth L, Hagana A, et al. Effectiveness of drug interventions to prevent delirium after surgery for older adults: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2026. PMID: 41690769. doi:10.1136/bmj-2025-085539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。